Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Master protocol of novel combination therapies in first-line advanced gastric or gastroesophageal junction adenocarcinoma
2024-510977-27-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of sabestomig, rilvegostomig, sonesitatug vedotin and volrustomig in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by AstraZeneca. Primary endpoints: Objective response rate and Progression-free survival at 6 months. Planned start Apr 2023; status: authorised.
02
Drugs
sabestomigrilvegostomigsonesitatug vedotinvolrustomig
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-510977-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510977-27-00.